PATENT CLAIM ANALYSIS

Application Number: 16133553
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "289000"]

Abstract:
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claim (Index 16):
A method for treating a human being with dextromethorphan, comprising administering to the human being a combination of dextromethorphan and bupropion twice daily for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan, wherein, after the combination is administered twice daily for eight consecutive days: 1) the human being has a C max  of dextromethorphan that is at least about 40 ng/mL and 2) the C max  of dextromethorphan is at least about 15 times the C max  of dextromethorphan that would result from administering the same amount of dextromethorphan twice daily without bupropion for eight consecutive days.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 97.0
- Lexical Diversity: 1.45455
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15688660', '15695995', '15691549', '15645939', '15691532']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8882889285944294
- 35 USC 102 Novelty (BERT): 0.6999472461179288
- Combined Prediction Score: 0.8694547603467794
- Mean Citation Score: 793.7393319999999
- Max Citation Score: 808.8913
- Similarity Product: 724.7875036939799

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test